Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

PXMD PaxMedica Inc

0.00 (0.00%)
Pre Market
Last Updated: 20:00:00
Delayed by 15 minutes


Draw Mode:

Volume 0
Bid Price 0.66
Ask Price 0.6601
News -
Day High


52 Week Range


Day Low
Company Name Stock Ticker Symbol Market Type
PaxMedica Inc PXMD NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.00 0.00% 0.6883 20:00:00
Open Price Low Price High Price Close Price Prev Close
Trades Volume Avg Volume 52 Week Range
0 0 - 0.372 - 25.50
Last Trade Time Type Quantity Stock Price Currency
- 0 $ 0.6883 USD

PaxMedica Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
5.11M 7.41M - 0 -18.29M -2.47 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

PaxMedica News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No PXMD Message Board. Create One! See More Posts on PXMD Message Board See More Message Board Posts

Historical PXMD Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week0.
1 Month0.7050.78020.650.713545479,452-0.0167-2.37%
3 Months0.671.1890.40110.78766553,452,5600.01832.73%
6 Months1.121.1890.3720.7934121,598,799-0.4317-38.54%
1 Year25.5025.500.3723.541,915,212-24.81-97.30%
3 Years110.50178.160.37226.571,841,265-109.81-99.38%
5 Years110.50178.160.37226.571,841,265-109.81-99.38%

PaxMedica Description

PaxMedica Inc an early clinical stage biopharmaceutical company focusing on the development of anti-purinergic therapies (or APT), for the treatment of neurodevelopmental disorders, including autism spectrum disorder (or ASD), and Fragile X syndrome tremor-ataxia (or FXTAS). It focuses on the development and testing of its lead program, PAX-101, an intravenous formulation of suramin, in the treatment of ASD and FXTAS. It is also focused on the treatment of Human African Trypanosomiasis (or HAT). Its candidate PAX-102, proprietary intranasal formulation of suramin, as well as other new chemical entities that are more targeted and highly selective antagonists of particular purinergic receptor subtypes.

Your Recent History

Delayed Upgrade Clock